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Abstract
Background: Numerous studies have shown that viral quasi-species with genetically diverse
envelope proteins (Env) replicate simultaneously in patients infected with the human
immunodeficiency virus type 1 (HIV-1). Less information is available concerning the extent that
envelope sequence diversity translates into a diversity of phenotypic properties, including infectivity
and resistance to entry inhibitors.
Methods: To study these questions, we isolated genetically distinct contemporaneous clonal viral
populations from the plasma of 5 HIV-1 infected individuals (n = 70), and evaluated the infectivity
of recombinant viruses expressing Env proteins from the clonal viruses in several target cells. The
sensitivity to entry inhibitors (enfuvirtide, TAK-799), soluble CD4 and monoclonal antibodies
(2G12, 48d, 2F5) was also evaluated for a subset of the recombinant viruses (n = 20).
Results: Even when comparisons were restricted to viruses with similar tropism, the infectivity
for a given target cell of viruses carrying different Env proteins from the same patient varied over
an approximately 10-fold range, and differences in their relative ability to infect different target cells
were also observed. Variable region haplotypes associated with high and low infectivity could be
identified for one patient. In addition, clones carrying unique mutations in V3 often displayed low
infectivity. No correlation was observed between viral infectivity and sensitivity to inhibition by any
of the six entry inhibitors evaluated, indicating that these properties can be dissociated. Significant
inter-patient differences, independent of infectivity, were observed for the sensitivity of Env
proteins to several entry inhibitors and their ability to infect different target cells.
Conclusion:  These findings demonstrate the marked functional heterogeneity of HIV-1 Env
proteins expressed by contemporaneous circulating viruses, and underscore the advantage of
clonal analyses in characterizing the spectrum of functional properties of the genetically diverse
viral populations present in a given patient.
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Background
The population of human immunodeficiency virus type 1
(HIV-1) present in a single infected patient at any given
time can show remarkable diversity. Moreover, the extent of
diversity can evolve over time and is different in different
genes. The most striking changes in diversity occur in the
envelope glycoproteins (Env). The initial transmission of
HIV-1 can result in infection of the new host with multiple
viruses expressing genetically diverse env sequences [1-6].
Early in the evolution of infection, however, viruses express-
ing extremely homeogeneous env sequences become domi-
nant, presumably reflecting the selection of viruses that are
best adapted for replication in available target cells, and/or
resistant to the nascent host immune response [1-3,7]. This
initial homogenization is followed by a period often lasting
many years, in which both the diversity of the env sequences
and the evolutionary distance from the initially dominant
strain increase linearly by approximately 1% per year [5,8-
17]. Subsequently, the extent of viral diversity begins to pla-
teau and, in the late stages of disease, a decline in viral diver-
sity can be observed [8,11,12,18].
Although genetic diversity of the viral env has been exten-
sively studied, less information is available concerning the
extent that these genetically diverse Env proteins also dis-
play functional diversity. Envelope sequences have been
amplified from plasma or short-term cell cultures and used
to produce recombinant or pseudotyped viruses expressing
primary env sequences [19-25]. Most studies have found
that only 40–70% of such viruses are infectious, but quan-
titative assessment of the replicative capacity of a large
number of viruses expressing different envelope sequences
from a single patient has not been reported.
It also remains unclear the extent to which other proper-
ties of the viral Env proteins are shared by coexisting
quasi-species from a given patient. Viral isolates obtained
from different individuals can differ in their sensitivity to
inhibition by chemokines [26-30], entry inhibitors [31-
37], certain monoclonal antibodies [32,38], and autolo-
gous serum [26,39], but the extent that different viruses
obtained from the same individual show similar sensitiv-
ity to a given entry inhibitor has not been extensively eval-
uated. Furthermore, replicative capacity, per se, can
influence the sensitivity of viruses to inhibitors of entry
[26,31,36,40], but it remains unknown whether or not
the sensitivity of viruses from a given patient to entry
inhibitors correlates closely with replicative capacity.
We have recently described an approach that allows the
direct isolation of contemporaneous clonal viruses from
the plasma of infected individuals, including viruses capa-
ble of using CCR5 and/or CXCR4 viral coreceptors
[41,42]. These viruses are potentially useful for the evalu-
ation of the functional correlates of env genetic diversity.
First, each clonal virus emerges independently, and there-
fore viruses with low infectivity are not lost through com-
petition with rapidly replicating viruses. Furthermore, the
env sequences expressed by these viruses are genetically
diverse, and the functional properties have not been mod-
ified by through mutation or recombination occurring
during PCR. In this study, we have created recombinant
viruses expressing Env proteins from these clonal viruses
in a reporter construct expressing luciferase activity, and
evaluated: i) the spectrum of infectivity observed for Env
proteins expressed by contemporaneous viral clones from
the same patient, ii) the ability of these viruses to infect
different target cells, and, iii) the relationship between
infectivity and the susceptibility of the Env proteins to sev-
eral different entry inhibitors.
Results
Diversity of envelope sequences
Phylogenetic analysis indicated that env sequences (C1-V2
region) for all clones from each patient clustered together
along with the consensus sequence obtained for bulk enve-
lope sequences amplified directly from plasma by RT-PCR
(Fig. 1). Viruses with both R5 and X4 tropism (see below)
Phylogenetic tree of envelope sequences of clonal viruses Figure 1
Phylogenetic tree of envelope sequences of clonal 
viruses. Shown is the neighbor-joining phylogenetic tree for 
nucleotide sequences coding the region of env encompassing 
C1 to V2 (corresponding to nucleotides 6440 – 6809 of 
HXB2) of the 70 clonal viruses evaluated in the study (open 
circles, strict R5 tropism, solid black circles, strict X4 tro-
pism; solid gray circles, dual tropism), the consensus 
sequence of the same region for viral RNA amplified by RT-
PCR from an aliquot of the plasma sample used to generate 
the clonal viruses (stars), and the sequence of the laboratory 
strain pNL4-3. Bootstrap values are also indicated. For 
patient 2, the consensus sequence of plasma viruses grouped 
with clonal viruses with X4 tropism at M26, and with clonal 
viruses with R5 tropism at M34.
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were isolated from 4 patients. For patients 1 and 2, sequences
for viruses with R5 tropism appeared to be phylogenetically
distinct from those of viruses with X4 (patient 2) or dual
(patient 1) tropism, and the sequence diversity among
viruses with similar tropism was lower than that of the entire
viral population. In contrast, for patients 4 and 5, envelope
sequences in the V1-V2 region for viruses with R5 tropism
were not segregated from those of viruses with X4 (patient 4)
or dual (patient 5) tropism. For patient 2, the consensus env
sequence for plasma viruses clustered with the sequences of
viruses with X4 tropism at month 26, but clustered with the
sequences of viruses with R5 tropism at month 34.
The nucleotide diversity of env sequences extending from
V1 to the middle of V4, calculated by the method of
Tajima-Nei, ranged from 0.018 – 0.060, values typical of
those obtained for sequences amplified from plasma by
RT-PCR. The greatest diversity was observed for patient 3,
despite that all viruses from this patient showed strict R5
tropism.
Infectivity of recombinant viruses carrying primary 
envelope sequences in U373-R5 and U373-X4 target cells
To explore the functional capacities of Env proteins
expressed by these clonal viruses, we generated recom-
binant reporter viruses in which the env sequence (gp120 +
the extracellular domain of gp41) was derived from the dif-
ferent clonal viruses, and evaluated the ability of these luci-
ferase-expressing viruses to infect U373 cells stably
expressing CD4 and either CCR5 or CXCR4 co-receptors.
All of the 70 recombinant viruses were infectious (Fig. 2).
Viruses with strict R5 tropism were identified in all patients
(n = 53), but clones with R5X4 tropism (n = 5) and/or strict
X4 tropism (n = 12) were also identified in 4 of the 5
patients studied. The infectivity of dual-tropic viruses
tended to be similar in the U373-R5 and U373-X4 target
cells (compare gray symbols in Figs. 2A and 2B). Without
exception, the infectivity of clones with R5 tropism was at
least 5-fold lower than the infectivity of recombinant
viruses carrying the Env from the laboratory-adapted strain
NL-AD8 [mean infectivity in U373-R5 cells: 22524 (RLU/
sec)/(ng p24/ml)]. The infectivity of some clones with X4
tropism was equivalent to that observed for recombinant
viruses carrying the Env from pNL4-3 [mean infectivity in
U373-X4 cells: 2650 (RLU/sec)/(ng p24/ml)].
Considerable variability was observed in the infectivity of
viruses carrying different env  sequences from the same
patient. When U373-R5 cells were used as targets, the dif-
ference in infectivity between the most and least infec-
tious viruses from each of the 5 patients averaged 1.0 ±
0.26 log10 (range 0.8 – 1.3 log10 difference). Some inter-
patient variability in infectivity was also observed. When
considered as a group, no significant differences in the
infectivity of clones carrying Env proteins from patients
Infectivity and co-receptor usage of envelope proteins  expressed by clonal viruses Figure 2
Infectivity and co-receptor usage of envelope pro-
teins expressed by clonal viruses. Recombinant reporter 
viruses were generated in which the env sequence (gp120 + 
the extracellular domain of gp41) was derived from clonal 
viruses isolated from plasma of patients chronically infected 
with HIV-1. The ability of these viruses, which express Renilla 
luciferase in the place of Nef, to infect U373 cells stably 
expressing CD4 and either CCR5 (panel A) or CXCR4 
(panel B) co-receptors was measured by evaluating luciferase 
expression in target cells 44 hours after infection. For patient 
2, clonal viruses were obtained from plasma samples 
obtained 8 months apart (26 and 34 months after initial diag-
nosis). The ability of all recombinant viruses to infect the two 
cell types was evaluated, but results are shown only for 
viruses that induced significant luciferase activity in the indi-
cated target cell type [>2 (RLU/sec)/(ng p24/ml)]. Viruses 
could be classified as having strict R5 tropism (open symbols) 
strict X4 tropism (solid black symbols) and dual tropism 
(sold gray symbols). Results for viruses expressing env 
sequences amplified by RT-PCR from patient plasma is also 
shown (stars). Each symbol is the mean of at least 3 inde-
pendent experiments; the mean coefficient of variation for 
these results is as follows: U373-R5 cells, 42% (range 3 – 
83%); U373-X4 cells, 50% (range 10 – 78%). For each patient, 
significant differences were found comparing the viruses with 
the highest and lowest infectivity (p < 0.05 – 0.001 by t-test).
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1–4 were observed, but the infectivity of clones from each
of these patients was significantly greater than that of
clones from patient 5 (p < 0.05 for all comparisons).
Impact of the intracellular portion of gp41 on viral 
infectivity
The intracellular portion of gp41 is known to interact with
Gag. To avoid potential incompatibilities between these
viral proteins [43,44], we initially evaluated the infectivity
of recombinant viruses in which both the intracellular por-
tion of gp41 and Gag were derived from the pNL4-3 viral
strain. Changes in the intracellular domain of gp41, how-
ever, have also been reported to influence Env function [45-
48], and it was important to evaluate the possibility that
incompatibilities between the extracellular domains of Env
in some of the viruses and the intracellular domain of gp41
from pNL4-3 contributed to the wide range of infectivities
observed. To do so, we compared the infectivity of selected
recombinant viruses in which the intracellular domain of
gp41 was derived either from pNL4-3 or from the primary
viral isolate. As shown in Fig. 3, the infectivities of the two
constructs were strongly correlated (Spearman r = 0.86; p <
0.0001). Viruses that demonstrated relatively poor infectiv-
ity when the intracellular domain of gp41 was derived from
pNL4-3 did not show improved infectivity when the
homologous intracellular domain of gp41 was used (e.g.,
the viruses with Env from patient 5 and the least infectious
virus from patient 4). Indeed, the use of the homologous
intracellular domain of gp41 led to a moderate loss in
infectivity for the viruses from patient 4 and some viruses
from patient 5, consistent with the possibility that incom-
patibilities existed in these cases between the gp41
sequences and the gag protein from pNL4-3.
Infectivity of recombinant viruses carrying primary 
envelope sequences in MT4-R5 cells
For all 70 recombinant viruses, the amount of luciferase
activity resulting from infection of U373 cells was greater
than that seen after infection of MT4-R5 cells. For each
patient, a significant correlation was observed between
the infectivity of viruses with R5-exclusive tropism for
U373-R5 and MT4-R5 target cells (p < 0.05 for all com-
parisons). As was observed when U373 cells were used as
targets, viruses carrying different env sequences from the
same patient showed considerable variability in infectiv-
ity when MT4-R5 cells were infected (Fig. 4A). The differ-
ence in infectivity between the most and least infectious
R5 viruses from each of the 5 patients averaged 1.2 ± 0.31
log10  (range 0.8 – 1.5 log10  difference). As indicated
above, the infectivity of viruses from patient 5 were strik-
ingly lower than that of viruses from other patients when
U373-R5 cells were used as targets. This difference was
less striking when MT4-R5 cells were infected (compare
Figs. 2A and 4A), although the infectivity of R5 viruses
from patient 5 remained significantly lower than that of
R5 viruses from patients 2 and 3 (p < 0.05 for both com-
parisons).
Interestingly, considerable variability was observed when
luciferase activity obtained following infection of the two
cell types was expressed as a ratio (Fig. 4B). This ratio did
not correlate with the infectivity of the viruses for U373
cells (Spearman r = 0.10, p = 0.49), but only viruses with
relatively low infectivity for MT4-R5 cells [i.e., <110 (RLU/
sec)/(ng p24/ml)] had values for this ratio that were
greater than 20 (Fig. 5). The level of expression of both
CD4 and CCR5 was approximately two-fold higher on
U373-R5 cells than on MT4-R5 cells (Fig. 6). Thus, a pos-
sible explanation for these observations is that the infec-
tivity of viruses for which a high ratio was observed are
particularly sensitive to the levels of expression of CD4
and/or co-receptor, although other differences between
U373-R5 cells and MT4-R5 cells may also influence the
ability of viruses carrying different envelopes to infect
these cell types.
The effect of the origin of the intracellular portion of gp41 on  infectivity Figure 3
The effect of the origin of the intracellular portion of 
gp41 on infectivity. For selected clonal viruses isolated from 
patient 3 (inverted triangles), patient 4 (triangles), patient 5 
(squares) or from the laboratory-adapted strain NL-AD8 (dia-
mond), two types of recombinant reporter viruses were gen-
erated, one in which gp120 + only the extracellular domain of 
gp41 was derived from the clonal virus (pNL4-3-ΔectoENV-
lucR, abscissa), and one in which gp120 and all of gp41 was 
derived from the clonal virus (pNL4-3-ΔENV-lucR vector, 
ordinate). The ability of these viruses to infect U373-R5 cells 
was compared by evaluating luciferase expression in the target 
cells 44 hours after infection. The infectivity of each pair of 
viruses was evaluated in three independent experiments, and 
each symbol represents the mean of these determinations. 
The dotted line is the line of identity. The correlation coeffi-
cient (Spearman) for the data shown is 0.86 (p < 0.0001).
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It is noteworthy that the proportion of viruses with a rela-
tively high infectivity ratio was different in different
patients. The infectivity ratios of clones from patients 1, 3
and 4 were significantly greater than that of patient 2 (p <
0.001, p < 0.001 and p < 0.05, respectively), and the infec-
tivity ratio of clones from patient 3 was also significantly
greater than that of patient 5 (p < 0.05).
Infectivity of recombinant viruses carrying envelope 
sequences amplified from plasma by RT-PCR
In parallel with studies evaluating the infectivity of recom-
binant viruses carrying env sequences derived from clonal
viruses, we evaluated the infectivity of recombinant
viruses expressing env  sequences amplified by RT-PCR
from viral RNA extracted from the same plasma specimen
from which the clonal viruses had been derived. The infec-
tivity of viruses carrying plasma-derived env sequences for
U373-R5 cells, although detectable in all cases except
patient 2, was generally low, and was less than that of the
clonal viruses from the same patient, usually by a substan-
tial margin (Fig. 2A). The infectivity of viruses expressing
plasma-derived  env  sequences for U373-X4 cells was
detectable in only two samples (Fig. 2B). In both of these
cases (patient 2, M26 and patient 4), clonal viruses with
X4 exclusive tropism had been identified. The failure to
detect infectivity of viruses carrying plasma-derived env
sequences in other samples from which clonal viruses
with strict X4 or dual tropism were identified may reflect
the somewhat lower infectivity of the viruses with X4 tro-
pism (e.g., patient 2, M34 and patient 5) and/or a lower
proportion of viruses with X4 tropism in the sample (e.g.,
patient 1). As was observed for viruses carrying env
Relationship between the infectivity of recombinant viruses  bearing envelope proteins from plasma viruses for MT4-R5  cells and U373-R5 cells Figure 5
Relationship between the infectivity of recombinant 
viruses bearing envelope proteins from plasma 
viruses for MT4-R5 cells and U373-R5 cells. Recom-
binant reporter viruses were generated as described in Fig. 1 
legend, and the ability of these viruses to infect MT4-R5 cells 
and U373-R5 cells was measured by evaluating luciferase 
expression in the target cells 44 hours after infection. For 
each of the 53 viruses with strict R5 tropism, the infectivity 
ratio (infectivity for U373-R5 cells/infectivity for MT4-R5 
cells) is expressed as a function of the infectivity for MT4-R5 
cells [(RLU/sec)/(ng p24/ml)]. A significant inverse correla-
tion between these parameters was observed (Spearman r = 
-0.64, p < 0.0001).
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Infectivity of recombinant viruses carrying primary Env  sequences in MT4-R5 cells Figure 4
Infectivity of recombinant viruses carrying primary 
Env sequences in MT4-R5 cells. (A) Recombinant 
reporter viruses were generated as described in Fig. 1 leg-
end, and the ability of these viruses to infect MT4-R5 cells 
was measured by evaluating luciferase expression in the tar-
get cells 44 hours after infection. For patient 2, clonal viruses 
were obtained from plasma samples obtained 8 months apart 
(26 and 34 months after initial diagnosis). The tropism of the 
recombinant viruses, as defined by their ability to infect 
U373-R5 and U373-X4 cells is shown: strict R5, open sym-
bols; dual, solid gray symbols; strict X4, solid black symbols. 
Results for viruses expressing env sequences amplified by RT-
PCR from patient plasma is also shown (stars). Each symbol 
is the mean of at least 3 independent experiments; the mean 
coefficient of variation for these results is 37% (range 1 – 
78%). For each patient, significant differences were found 
comparing the viruses with the highest and lowest infectivity 
(p < 0.05 – 0.005 by t-test). (B) For each recombinant virus, 
the infectivity [(RLU/sec)/(ng p24/ml)] observed using U373 
target cells and MT4-R5 target cells is expressed as a ratio.
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sequences derived from clonal viruses, the infectivity of
viruses carrying plasma-derived env sequences for MT4-R5
cells was usually reduced compared to that observed for
U373 cells (Fig. 4A). Indeed, for patients 1 and 5, low
level infectivity was detected toward U373-R5 cells, but
infectivity was below detection when MT4-R5 cells were
targeted.
Sensitivity of recombinant viruses carrying primary 
envelope sequences to entry inhibitors
Because the infectivity of clonal viruses carrying different
env sequences from a given patient varied over a wide
range, these viruses were useful in exploring the possible
relationship between infectivity and sensitivity to inhibi-
tion by entry inhibitors. To do so, clonal viruses with R5-
tropism that exhibited a spectrum of infectivities towards
U373-R5 cells and/or MT4-R5 cells were selected from 4
of the patients (Figs. 7A and 7B). For each of these 20
viruses, the IC50s were determined on U373-R5 target
cells for two entry inhibitors (enfuvirtide and TAK-799),
soluble CD4, and neutralizing monoclonal antibodies
recognizing either gp120 (2G12, 48d) or gp41 (2F5). No
significant correlations were observed between the IC50s
of these six inhibitors and the infectivity of the clonal
viruses for either U373-R5 cells or MT4-R5 cells (data not
shown, p > 0.09 for all Spearman correlations).
Viruses from different patients did, however, demonstrate
differential sensitivity to these entry inhibitors, independ-
ent of infectivity (Fig. 7). Thus, significant differences in
the median sensitivity to entry inhibitors by clonal viruses
from different patients was observed by ANOVA for all
entry inhibitors except TAK-799 (p values for Kruskal-
Wallis test: p < 0.001 – 0.05), and for each of these inhib-
itors, significant differences in were also identified in pair-
wise comparisons of IC50s for viruses from different
patients (Fig. 7).
Genotype-phenotype correlations
Nucleotide sequences for env extending from the signal
peptide to mid C4 region were available for all clones. The
PSSM score developed by Jensen et al. [49] correctly dis-
tinguished all clones with R5-exclusive tropism and X4-
exclusive tropism, even though viruses from two of the
patients were non-B subtypes. Three of the 6 Env proteins
with dual tropism, however, were predicted to exhibit R5-
exclusive tropism (one clone each from patients 1, 2 and
5). The amino acid sequence of the V3 region of these
dual-tropic clones from patients 1 and 2 differed at 6 and
1 positions, respectively, compared to that of the most
similar R5-tropic Env identified in that patient, and these
differences may explain the change in tropism. The V3
region of the misidentified dual-tropic envelope sequence
from patient 5, however, was identical to that of other Env
Expression of CD4 and CCR5 on U373-R5 cells and MT4-R5  cells Figure 6
Expression of CD4 and CCR5 on U373-R5 cells and 
MT4-R5 cells. Cells were resuspended in PBS containing 
20% human serum and incubated with directly-conjugated 
monoclonal antibodies or isotype-matched control antibod-
ies conjugated with the same flurochrome. (A) CD4 expres-
sion on U373-R5 cells (thin solid line) and MT4-R5 cells 
(heavy solid line) detected using FITC-labelled mouse anti-
human CD4 monoclonal antibody (clone RPA-T4). Binding of 
an isotype-matched control antibody conjugated with FITC is 
shown in the corresponding dashed lines. (B) CCR5 expres-
sion on U373-R5 cells (thin solid line) and MT4-R5 cells 
(heavy solid line) detected using phycoerythrin-conjugated 
mouse anti-human CCR5 monoclonal antibody (clone 2D7). 
Binding of an isotype-matched control antibody conjugated 
with phycoerythrin to these cells is shown in the corre-
sponding dashed lines.
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Sensitivity of recombinant viruses carrying primary envelope sequences to entry inhibitors Figure 7
Sensitivity of recombinant viruses carrying primary envelope sequences to entry inhibitors. Clonal viruses with 
R5-tropism exhibiting a spectrum of infectivities towards U373-R5 cells (panel A) and/or MT4-R5 cells (panel B) were selected 
from among those obtained from patients 1–4. For each of these 20 viruses, the IC50s were determined on U373-R5 cells for 
soluble CD4 (C), enfuvirtide (E), TAK-799 (G), and neutralizing monoclonal antibodies 2F5 (D), 2G12 (F), and 48d (H). Each 
symbol represents the mean of three independent determinations. For all inhibitors except TAK-799, significant patient-spe-
cific differences in IC50 were observed using the Kruskal-Wallis test. Brackets indicate significant pairwise differences in post-
test comparisons performed using Dunn's multiple comparison test (* p < 0.05; ** p < 0.01). For patient 2, clonal viruses were 
obtained from plasma samples obtained at both 26 months (solid symbols) and 34 months (open symbols) after initial diagnosis.
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with R5-exclusive tropism, indicating that sequences out-
side V3 influenced the tropism of this Env.
In general, viruses with strict R5-tropism from the same
individual expressed a relatively small number of haplo-
types within a given variable (V) region. For example, the
number of distinct haplotypes identified for the V3 region
ranged from 1 (patient 1) to 4 (patient 2). Significant dif-
ferences in the infectivity of R5-tropic viruses as a function
of haplotype were observed for the variable regions 2 and
3 (V2 and V3) of patient 2 (p < 0.02 and p < 0.03 respec-
tively using the Kruskal-Wallis test). As shown in Fig. 8,
the viruses from this patient expressing V3 region haplo-
types 2 and 3 were significantly less infectious than those
expressing haplotype 1 (p < 0.01 using the Mann-Whitney
test), and viruses expressing the V2 region haplotype 4
were less infectious than those expressing the V2 region
haplotypes 1 – 3 (p < 0.001). Most of the viruses express-
ing the V2 haplotype associated with low infectivity (hap-
lotype 4) also expressed V3 haplotypes associated with
low infectivity. However, one of the viruses expressed this
V2 haplotype in association with the V3 haplotype 1,
which was usually associated with good infectivity (red
arrow in Fig. 8A). The infectivity of this virus was, never-
theless, low (red arrow in Fig. 8B), suggesting that expres-
sion of the V2 haplotype 4 was a major determinant for
low infectivity in this patient. It is noteworthy that clones
from patient 2 expressing the V2 haplotype 4 were
obtained only from the plasma sample obtained at month
34, and 9/13 clones with R5-tropism isolated at this time
point expressed this V2 haplotype.
No significant associations between infectivity and haplo-
type were observed for the variable regions expressed by
the other patients, and no association between infectivity
and the haplotypes in the constant regions were identi-
fied. One factor that could confound such analyses is the
presence of deleterious mutations elsewhere in the enve-
lope sequence. In this regard, we found that four of the 53
viruses with strict R5 tropism had V3 sequences contain-
ing a single amino acid polymorphism not seen in any
other sequence from that patient. The recombinant
viruses carrying 3 of these unique V3 polymorphisms had
the lowest infectivity for U373-R5 cells of any virus evalu-
ated from that sample.
Discussion
In this study we have explored the functional properties of
Env proteins from contemporaneous HIV-1 biological
clones isolated from the plasma of chronically infected
patients. Even when comparisons were restricted to
viruses with similar tropism, these genetically diverse Env
proteins were found to exhibit striking functional diver-
sity, including, i) a wide range of infectivities for a given
target cell, ii) differences in relative ability to infect differ-
ent target cells, and iii) differences in sensitivity to certain
entry inhibitors. In addition to the functional diversity
observed among viruses from a single patient, significant
inter-patient differences were also observed for some char-
acteristics of Env proteins, including sensitivity to several
different entry inhibitors and the relative ability of viruses
to infect different target cells. Interestingly, no correlation
was observed between viral infectivity and sensitivity to
entry inhibitors, indicating that these properties are, to
some extent, dissociable. These findings demonstrate the
marked functional heterogeneity of HIV-1 Env proteins
expressed by contemporaneous circulating viruses, and
underscore the advantage of clonal analyses in character-
izing such viral populations.
The observation that Env proteins expressed by contem-
poraneous viruses display a broad spectrum of infectivity
towards a given target cell raises the question of the forces
responsible for this functional diversity. One factor that
can drive the development of diversity is the selection in a
single patient of numerous viral subpopulations with dis-
tinct Env functional properties. Genetically distinct viral
populations replicating in different tissues or cellular
compartments have been identified in numerous studies
[50-54]. Such populations can also result in functional
diversity, as illustrated by the obvious example of the
coexistence of viruses with different tropism. Indeed, we
found that the coexistence of viruses with R5 and X4 tro-
pism could make an important contribution to overall
genetic diversity in patients from whom both populations
were isolated.
The high mutation and recombination rates of HIV-1 are
also likely to have an important impact on infectivity.
Because of the numerous structural constraints in viral
proteins, including Env, many mutations will prove to be
deleterious for fitness. Similarly, recombination events
that shuffle env segments can modify the function of Env
proteins [55,56]. Indeed, genetic evidence supports the
idea that purifying selection against deleterious mutations
is occurring in the env  region [57]. In this regard, we
observed that 3 of 4 viruses in which V3 sequences con-
tained a single amino acid polymorphism not seen in any
other sequence from that patient had low infectivity. The
association of such rare polymorphisms with poor infec-
tivity is consistent with the possibility that the deleterious
mutations contribute to the wide spectrum infectivity
observed in these studies, although further studies are
required to directly demonstrate the impact of such spe-
cific genetic differences on viral infectivity.
The extent that genetic differences deleterious for viral
replication accumulate because they are associated with
escape from immune responses is also an important issue.
In this regard, we observed that a V2 haplotype associatedRetrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
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Expression of V2 and V3 region haplotypes in Env proteins of clonal viruses from patient 2 and viral infectivity Figure 8
Expression of V2 and V3 region haplotypes in Env proteins of clonal viruses from patient 2 and viral infectivity. 
(A) The haplotypes in the V2 region (left) and V3 region (right) of the Env proteins expressed by the 17 clonal viruses from 
patient 2 with strict R5 tropism are shown. The consensus amino sequence is shown on the top line, and only amio acids dif-
fering from the consensus sequence are shown for each clone. For each variable region, sequences that are identical or that dif-
fer by a single amino acid substitution not identified in another sequence are highlighted by the same color, and these 
haplotypes are also identifed by numbers adjacent to the brackets. The red arrow indicates the envelope expressing the V2 
region haplotype 4 associated with the V3 region haplotype 1 (see text). (B) The infectivity of recombinant viruses expressing 
these Env proteins using U373-R5 cells is shown. For each of the variable regions, the color of the symbols corresponds to that 
of the V region haplotype expressed by that virus. The red arrow indicates the infectivity of the clone expressing the V2 region 
haplotype 4 associated with the V3 region haplotype 1.
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with reduced viral infectivity emerged in patient 2 over an
8 month interval, and had become the dominant haplo-
type. This haplotype differed by a single amino acid
change from another haplotype observed in this individ-
ual (Fig. 8). Such a modification would be typical of
escape from neutralizing antibodies or cytotoxic T-cells
targeting this epitope, although other explanations are
also possible (e.g., adaptation of the Env proteins to
improve the targeting of a specific cell type or fixation of
a deleterious mutation through stochastic processes). Fur-
ther studies comparing the spectrum of infectivity of Env
proteins present in the genetically homogeneous viral
populations of viruses present immediately before sero-
conversion with that observed following the development
of the anti-viral immune response will help define the
extent that selection of variants associated with immune
escape affects Env function.
The possibility that viral evolution during in vitro culture
contributed to diversity should also be considered. For
example, greatest viral diversity was observed for patient
3, and clones from this patient emerged later than those
from the other patients. However, control experiments
(see Materials and Methods) showed no evidence for viral
evolution during culture. In particular, the absence of pol-
ymorphic bases in the sequences of the viral clones indi-
cates that variants were not emerging to the extent that
they were detectable by bulk sequencing, and therefore
were not sufficiently abundant to influence either viral
diversity or the assessment of infectivity.
The spectrum of Env infectivity in vivo is almost certainly
greater than observed in our study. The Env proteins stud-
ied by us were derived from viruses capable of produc-
tively infecting MT4-R5 cells. We must assume that the env
sequences of these viruses were enriched for those with
high infectivity in this cell system, and Env proteins carry-
ing lethal mutations or mutations preventing efficient
propagation in MT4-R5 cell cultures would not be sam-
pled. We found that recombinant viruses produced using
bulk env sequences amplified directly from plasma by RT-
PCR had an infectivity that was lower than that of recom-
binant viruses carrying Env proteins from the clonal
viruses derived from the same sample, as would be
expected if a significant proportion of viruses present in
plasma carry Env proteins that are noninfectious or whose
infectivity is too low to permit emergence of clones during
in vitro culture. The finding in previous studies that a sub-
stantial portion of viruses expressing env sequences ampli-
fied from plasma by RT-PCR show low or undetectable
infectivity is also compatible with this interpretation [19-
23,53,58]. It should be emphasized, however, that addi-
tional artifacts may also contribute to the low infectivity
observed in our study for viruses carrying bulk env
sequences amplified from plasma by RT-PCR, such that
the infectivity of the recombinant viruses would not be
reflective of viruses in plasma. First, recombinant viruses
formed using mixtures of sequences amplified from
plasma will express heterotrimeric Env proteins, includ-
ing, for some samples, trimers containing sequences with
both X4 and R5 tropism. In this regard, our preliminary
results suggest that the infectivity of viruses generated
using mixtures of clonal env sequences may be lower than
the mean infectivity of viruses expressing each of these env
sequences as homotrimers. In addition, during the ampli-
fication of env  sequences from plasma, recombination
between the heterogeneous target sequences can occur,
and may form sequences in which incompatibilities
between Env segments are deleterious to infectivity. In
view of these uncertainties, further studies will be required
to fully define the spectrum of infectivity of Env proteins
expressed by viruses in plasma.
An interesting observation from our study was the
absence of correlation between the infectivity of the
recombinant viruses studied and their susceptibility to
several different entry inhibitors or neutralizing antibod-
ies. The affinity of Env-coreceptor interactions is one fac-
tor that can influence both Env fusion kinetics and the
sensitivity of Env to the inhibition by enfuvirtide and
TAK-779 [35,36,56,59], although mutations that modify
sensitivity to co-receptor antagonists without modifying
fusion kinetics have also been described [36,60]. The fail-
ure to find a correlation between Env infectivity and sen-
sitivity to these inhibitors suggests that differences
affecting membrane fusion that are independent of Env-
coreceptor affinity (e.g., "fusogenicity") or differences
affecting other Env properties (e.g., the expression or sta-
bility of Env trimers) make an important contribution to
the wide spectrum of Env infectivities observed in this
study.
We did observe, however, that sensitivity to inhibition by
soluble CD4, enfuvirtide, and three different neutralizing
antibodies were properties that were shared by viruses
from a given patient, independent of their infectivity. Sim-
ilarly, Ray et al. found differences in enfuvirtide sensitivity
comparing Env clones isolated from different patients
[58]. These findings suggest that genetic determinants
important in defining the sensitivity to these entry inhib-
itors lie in regions that are not necessarily subject to exten-
sive diversity. For example, determinants in the relatively
well conserved membrane proximal ectodomain of gp41
appear to be important in determining sensitivity to both
enfuvirtide and the monoclonal antibody 2F5 [61,62].
Determinants of sensitivity to inhibitors of coreceptor
binding appear to be subject to greater intra-patient varia-
bility. No patient-specific differences in sensitivity to TAK-
779 was observed in our study, and considerable variabil-
ity in sensitivity of individual Env clones from a givenRetrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
Page 11 of 16
(page number not for citation purposes)
patient has been reported for several other coreceptor
antagonists [58]. Thus, the impact of viral diversity on
sensitivity to entry inhibitors is likely to differ for inhibi-
tors with different modes of action. Our findings suggest,
however, that resistance to entry inhibitors is not likely to
be a useful surrogate marker for viral infectivity.
Conclusion
These studies highlight the difficulty in defining the repli-
cative "fitness" of viral Env proteins from a given patient,
because viruses can display a large spectrum of Env infec-
tivities and this spectrum is different in different cell types.
Similarly, our studies confirm that considerable variabil-
ity can be encountered in the sensitivity of individual Env
proteins to entry inhibitors, and that this parameter can
vary independently of Env infectivity. Only through
clonal analysis can the heterogeneity of these Env proper-
ties be fully appreciated. As discussed above, further char-
acterization of the spectrum of Env infectivity at different
stages of disease evolution should provide insights into
factors that govern viral pathogenesis. Because these
parameters may differ in different individuals, this infor-
mation may prove to be of prognostic significance.
Methods
Patients
Clonal viral populations were obtained from five patients
chronically infected with HIV-1. Clinical information of
these patients is summarized in Table 1. All patients were
evaluated at the Hôpital Bichat – Claude Bernard, and
informed consent was obtained prior to participation in
the study. Three of the patients were not receiving treat-
ment with antiretroviral drugs at the time of initial evalu-
ation (patients 1–3). Patient 1 had never been treated.
Patient 2 had received intermittent treatment with several
regimens containing nucleoside analog reverse tran-
scriptase (RT) inhibitors and protease inhibitors over a
two year period, but had discontinued therapy 2 months
before evaluation. Patient 3 had been treated for 1 year
with AZT+3TC+efavirenz, but treatment had been discon-
tinued for 3 years prior to evaluation. Patients 4 and 5 had
a ≥ 2 year history of treatment failure. Both had been
treated initially with nucleoside analog RT inhibitors, and
subsequently received regimens also including non-nucl-
eoside RT inhibitors, protease inhibitors and/or enfuvir-
tide in various combinations, but plasma virus had never
become undetectable. Neither patient had received antivi-
ral agents that target viral entry for at least 1 year prior to
evaluation. For patient 2, clonal viral populations were
obtained from two different plasma samples obtained
eight months apart.
Clonal viral populations
Clonal viral populations were obtained as previously
described [41,42]. Briefly, MT4-R5 cells, expressing CCR5
and CXCR4 receptors, were resuspended at 2 × 106 cells/
ml in complete medium containing 1% (v/v) DMSO, and
0.25 ml aliquots were distributed in 24-well plates. An
equal volume of plasma, diluted in complete medium
containing (final concentration) 1% DMSO and 2 μg/ml
DEAE-dextran, was added to each well. The plates were
centrifuged (860 xg; 2 hours; 22°C), and cultured for 4
hours at 37°C to permit viral entry. Cells were recovered,
washed once, and 200 μl aliquots containing 2 × 104 cells
were distributed into 96-well plates. The cultures were
maintained at 37°C in 5% CO2, and were passaged with
a 1:10 dilution every 7 days. Cultures were inspected by
light microscopy, and when patent cytopathic changes
were observed, the culture supernatant and the cell pellet
from infected wells were recovered separately and frozen
at -80°C. If viral replication was observed in >20% of the
wells, the experiment was repeated after further dilution
of the plasma. The days in culture at which the clones
from different patients emerged is shown in Table 1. Sev-
enty-five percent of all clones had emerged by day 24.
Findings in this and our prior studies [41,42] supported
the conclusion that viral evolution was not occurring dur-
ing culture. In control experiments, pNL4-3-derived
viruses containing protease mutations that substantially
impaired viral fitness (replicative capacity 10–20% of
wild-type virus) were used in our protocol to generate
Table 1: Clinical characteristics of patients at time of study and number of clonal viruses obtained
Patient Age/Sex Months since 
diagnosis
Treatment* Viral Load 
(log10)
CD4 T-cells 
(cells/μl)
Number of 
clones
Time to 
emergence of 
clones (days)
1 35/M 17 none 5.52 276 9 18 – 26
2 38/M 26 none 6.67 7 9 11 – 20
34 3TC ddI LPV # 6.32 18 16 11 – 20
3 41/M 210 none 6.22 151 16 20 – 36
4 38/M 114 3TC SQV/RTV 5.43 11 12 14 – 27
5 40/M 139 3TC ddI TDF 
TPV/RTV APV
5.33 8 8 10 – 21
*Abbreviations for antiretroviral drugs are as follows: amprenavir (APV), didanosine (ddI), lamivudine (3TC), ritonavir (RTV), saquinavir (SQV), 
tenofovir (TDF), tipranavir (TPV). #Poor compliance suspected.Retrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
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clonal viruses, and the protease region from 36 different
clones was sequenced. Without exception, these
sequences were identical to the original plasmid (14,256
bases) and no evidence of reversion of the deleterious
mutations was observed, despite that reversion of any of
the mutations would have substantially improved fitness.
In addition, proviral DNA (including env) was amplified
and sequenced for every clone used in our study, and
without exception, no ambiguous bases were identified.
The absence of detectable polymorphisms is consistent
with the interpretation that variants were not emerging
during culture to the extent that their presence was detect-
able by bulk sequencing (i.e., >10%).
Vectors
We have previously described a pNL4-3-derived proviral
vector in which the env  sequence coding for most of
gp120 and the ectodomain of gp41 (nucleotides 6480 to
8263) has been deleted and replaced by a linker sequence
containing a unique MluI restriction site [34]. To create a
similar vector expressing Renilla luciferase in place of Nef,
the BamHI – NcoI fragment was removed, and the
remaining fragment was ligated with the BamHI – KpnI
fragment from pTN7-NL [63] and the KpnI – NcoI frag-
ment from pNL4-3, creating (pNL4-3-ΔectoENV-lucR).
An analogous proviral vector was also constructed in
which all of the env sequence except for that coding the 13
N-terminal amino acids of gp120 and the 29 C-terminal
amino acids of gp41 (nucleotides 6344–8691) has been
deleted and replaced by a linker sequence containing a
unique NheI restriction site (pNL4-3-ΔENV-lucR).
Amplification of proviral DNA
DNA was extracted from the infected cell pellets using a
QIAamp Viral DNA mini kit (Qiagen, Valencia, CA),
resuspended in 100 μl of 10 mM Tris buffer containing 1
mM EDTA, and used as a template to amplify env frag-
ments. To amplify the 2.2 kb fragment that spans the env
region deleted from the pNL4-3-ΔectoENV-lucR vector
and also containing 147 bp (N-terminal) and 258 bp (C-
terminal) extensions to allow homologous recombina-
tion with this vector, reactions (50 μl) contained 2 μl
DNA, 200 μM each dNTPs, 1.5 mM Mg2+, 0.5 μM each oli-
gonucleotides E5 (5'-GTCTATTATGGGGTACCTGTGT-
GGA) and FuB (5'-GGTGGTAGCTGAAGAGGCACAGG),
1U Phusion hot start DNA polymerase (Finnzymes,
Espoo, Finland), and 1X Phusion HF reaction buffer.
Cycling conditions were as follows: 98°C for 30 sec, fol-
lowed by 5 cycles at 98°C for 5 sec, 72°C for 5 sec and
72°C for 90 sec each; 5 cycles at 98°C for 5 sec, 70°C for
5 sec and 72°C for 90 sec each; 30 cycles at 98°C for 5 sec,
68°C for 20 sec and 72°C for 90 sec each; with a final step
at 72°C for 10 min. PCR products were purified by
QIAquick PCR Purification Kit (Qiagen). Aliquots of the
purified DNA was electrophoresed into agarose gels and
stained with ethidium bromide to verifiy that a single
band of appropriate size had been amplified and to per-
mit quantification of the product. The 2.6 kb fragment
that spans the env region deleted from the pNL4-3-ΔENV-
lucR vector and also comprises 143 bp (N-terminal) and
104 bp (C-terminal) extensions to allow homologous
recombination with this vector was amplified using simi-
lar conditions, except that oligonucleotides EB1 (5'GAAA-
GAGCAGAAGACAGTGGCAATGA) and EB2 (5'-
ACTTGCCACCCATCTTATAGCAAA) were used, and
cycling conditions were: 98°C for 30 sec, followed by 40
cycles at 98°C for 5 sec, 70°C for 20 sec and 72°C for 90
sec each; and a final step at 72°C for 10 min.
To amplify env sequences present in plasma, RNA was iso-
lated from plasma using a QIAamp RNA Blood Mini Kit
(Qiagen), and cDNA was synthesized using SuperScript III
reverse transcriptase (Invitrogen, Carlsbad, CA) and ran-
dom hexamer primers. Env sequences were amplified in a
single reaction using the protocol described above.
Cell culture
293T cells and U373-CD4 cells were cultured in Dul-
becco's modified Eagle medium supplemented with 10%
fetal calf serum, 100 U/ml penicillin G and 100 μg/ml
streptomycin (complete medium). MT4-R5 cells were cul-
tured in similarly supplemented RPMI-1640 medium. For
U373-CD4 cells stably expressing CCR5 or CXCR4 [64],
medium also contained 10 μg/ml puromycin and 100 μg/
ml hygromycin B.
Production of recombinant viruses
The techniques used to produce recombinant viruses have
previously been described [34,65,66]. Briefly, 293T cells
that had been grown to 80% confluency in T25 flasks were
co-transfected with 8 μg of MluI-linearized pNL4-3-Δec-
toENV-lucR vector (or NheI-linearized pNL4-3-ΔENV-
lucR vector) and 1 μg of the corresponding PCR product
using the calcium phosphate precipitation method, and
cultured in 3 ml of complete medium. After 18 h, cells
were washed with phosphate-buffered saline (PBS) and
culture medium was replaced. Forty-four h after transfec-
tion culture medium was recovered and centrifuged (800
xg; 10 min), and p24 antigen present in the supernatant
was measured using an enzyme-linked immunosorbent
assay (Innotest HIV antigen mAB, Innogenetics, Gent, Bel-
gium).
Evaluation of viral infectivity
The infectivity of recombinant viruses for different target
cell types was determined by measuring luciferase activity.
To do so, target cells were plated in black-wall, clear bot-
tom 96-well plates (Greiner, Courtaboeuf, France). U373
cells were plated at 2 × 103 cells/well 48 h prior to infec-
tion; MT4-R5 cells were plated at 5 × 104 cells/well on theRetrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
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day of infection. Medium was removed and replaced with
60  μl of complete medium containing serial two-fold
dilutions of freshly harvested supernatants from trans-
fected cells containing 0.069 – 50 ng p24/ml. Forty-four
hours after infection, 20 μl of 4X luciferase lysis buffer
(Renilla luciferase assay system, Promega, Charbonnières,
France) was added to each well, and plates were main-
tained at room temperature for 30 min. Wells were
sequentially injected with 100 μl of luciferase substrate
(Promega), and 3 seconds later, light emission (relative
light units, RLU) was measured over a two sec interval
using a Microlumat LB96P luminometer (Berthold, Oak
Ridge, TN). Each sample was evaluated in triplicate. RLU
were plotted as a function of amount of p24 used to infect
the cells, and infectivity was defined as the slope [(RLU/
sec)/(ng p24/ml)] as determined by linear regression; in
this analysis, each replicate RLU value was treated as an
individual point.
In preliminary experiments, we compared the infectivity
of viruses obtained after transfection of 293T cells with
proviral plasmids, and viruses created by recombination
between env sequences amplified from the same plasmid
and the pNL4-3-derived ΔEnv vector according to our pro-
tocol. The infectivity of the viruses produced through
recombination was 89 ± 37% (mean ± SD; n = 5) of that
observed for viruses obtained directly by transfection (p >
0.2 by paired t-test).
For each viral Env protein studied, infectivity was deter-
mined for each cell type in at least three independent
experiments. Infection was considered undetectable if the
RLU observed for the highest concentration of p24 evalu-
ated was less than 500 RLU/sec (i.e., infectivity <2 (RLU/
sec)/(ng p24/ml). The mean coefficient of variation for
clonal Env proteins with detectable infectivity was as fol-
lows: U373-R5 cells (n = 58), 42%; U373-X4 cells (n =
17), 50%; MT4-R5 cells (n = 70), 37%.
Inhibition of infectivity by entry inhibitors
To measure the susceptibility of recombinant viruses to
inhibition by enfuvirtide and TAK-799, U373-R5 cells
were plated at a density of 6 × 103 cells/well as described
above, and infected with the same dose of recombinant
virus in the absence or the presence of increasing concen-
trations of enfuvirtide (1.6 to 5,000 ng/ml; T20, American
Peptide Company, Sunnyvale, CA) or TAK-799 (0.8 to
2500 nM; NIH AIDS Research and Reference Reagent Pro-
gram). Forty four hours after infection, luciferase activity
was measured as described above. For each virus, an
amount of p24 was used that gave approximately 5 × 104
RLU/second for cells infected in the absence of inhibitor.
Each experimental condition was evaluated in triplicate.
To determine the concentration of inhibitor required for
reduce viral infectivity by 50% (IC50), data was fitted to a
sigmoid dose-response curve with variable slope.
The susceptibility of recombinant viruses to inhibition by
soluble CD4 (R&D Systems, Minneapolis, MN) and mon-
oclonal antibodies 48d (human anti-gp120, NIH AIDS
Research and Reference Reagent Program), 2G12 (human
anti-gp120, Polymun Scientific, Vienna, Austria) and 2F5
(human anti-gp41, Polymun Scientific) was measured by
similar techniques, except that recombinant viruses were
preincubated for 1 h at 37°C with serial three-fold dilu-
tions of soluble CD4 or monoclonal antibodies, before
using 60 μl of the mixture to infect target cells. For each
viral Env, infectivity was determined for each inhibitor
cell type in at least two, and usually three independent
experiments. The mean coefficient of variation for the six
entry inhibitors ranged from 25% (enfuvirtide) to 64%
(soluble CD4).
Cytofluorometry
U373 cells were detached by incubation in PBS containing
0.8% EDTA. Cells were resuspended in PBS containing
20% human serum (1 × 106 cells; 100 μl) and 10 μl of one
of the following monoclonal antibodies: phycoerythrin-
conjugated mouse anti-human CCR5 (clone 2D7), phy-
coerythrin-conjugated mouse anti-human CXCR4 (clone
12G5), FITC-conjugated mouse anti-human CD4 (clone
RPA-T4), or similarly conjugated isotype-matched control
antibodies (BD Biosciences, San Jose, CA). Following a 1
h incubation at 4°C, cells were washed once and analyzed
using a FACSCalibur flow cytometer (BD Biosciences).
Analysis was restricted to viable cells, identified on the
basis of forward and 90° scatter.
Data analysis
Results are expressed as mean ± SD unless otherwise indi-
cated. Comparisons between groups were performed
using the Kruskal-Wallis test. Post test comparisons, per-
formed only if p < 0.05, were made using Dunn's multiple
comparison test. Correlations were evaluated using the
Spearman test. Nucleotide diversity was determined using
the method of Tajima and Nei [67].
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
TN, FB performed the experiments and contributed to the
analysis of data and writing the manuscript. BL, FM
designed and constructed the vectors used and partici-
pated in design of the studies. CC contributed to obtain-
ing the viral clones and the genetic studies. FC, AJH
participated in the design of the study, the analysis of dataRetrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
Page 14 of 16
(page number not for citation purposes)
and wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported in part by grants from the Agence Nationale de 
Recherches sur le SIDA (ANRS, 2005/002) and from Sidaction. The follow-
ing reagent was obtained through the AIDS Research and Reference Rea-
gent Program, Division of AIDS, NIAID, NIH: monoclonal antibody 48d 
from Dr. James E. Robinson; TAK-799 with permission of Takeda Chemical 
Industries, Ltd.
References
1. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds
P: Selection for specific sequences in the external envelope
protein of human immunodeficiency virus type 1 upon pri-
mary infection.  J Virol 1993, 67:3345-3356.
2. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L:
Virus population homogenization following acute human
immunodeficiency virus type 1 infection.  J Virol 2002,
76:11953-11959.
3. Poss M, Rodrigo AG, Gosink JJ, Learn GH, de Vange Panteleeff D,
Martin HL Jr., Bwayo J, Kreiss JK, Overbaugh J: Evolution of enve-
lope sequences from the genital tract and peripheral blood
of women infected with clade A human immunodeficiency
virus type 1.  J Virol 1998, 72:8240-8251.
4. Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwany-
umba F, Claeys P, Chohan V, Mandaliya K, Temmerman M, Plum J:
Diversity of the human immunodeficiency virus type 1 (HIV-
1) env sequence after vertical transmission in mother-child
pairs infected with HIV-1 subtype A.  J Virol 2003, 77:3050-3057.
5. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos
KM, Hicks CB, Eron JJ Jr., Swanstrom R: Multiple V1/V2 env vari-
ants are frequently present during primary infection with
human immunodeficiency virus type 1.  J Virol 2004,
78:11208-11218.
6. Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES,
Overbaugh J: Human immunodeficiency virus type 1 (HIV-1)
diversity at time of infection is not restricted to certain risk
groups or specific HIV-1 subtypes.  J Virol 2004, 78:7279-7283.
7. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R,
Heldebrant C, Conrad A, Busch M: Homogeneous quasispecies
in 16 out of 17 individuals during very early HIV-1 primary
infection.  Aids 2002, 16:189-195.
8. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber
B, Mullins JI: Slower evolution of human immunodeficiency
virus type 1 quasispecies during progression to AIDS.  J Virol
1997, 71:7498-7508.
9. Liu SL, Schacker T, Musey L, Shriner D, McElrath MJ, Corey L, Mullins
JI: Divergent patterns of progression to AIDS after infection
from the same source: human immunodeficiency virus type
1 evolution and antiviral responses.  J Virol 1997, 71:4284-4295.
10. Lukashov VV, Kuiken CL, Goudsmit J: Intrahost human immuno-
deficiency virus type 1 evolution is related to length of the
immunocompetent period.  J Virol 1995, 69:6911-6916.
11. McDonald RA, Mayers DL, Chung RC, Wagner KF, Ratto-Kim S, Birx
DL, Michael NL: Evolution of human immunodeficiency virus
type 1 env sequence variation in patients with diverse rates
of disease progression and T-cell function.  J Virol 1997,
71:1871-1879.
12. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May
RM: Antigenic diversity thresholds and the development of
AIDS.  Science 1991, 254:963-969.
13. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Far-
zadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins
JI: Consistent viral evolutionary changes associated with the
progression of human immunodeficiency virus type 1 infec-
tion.  J Virol 1999, 73:10489-10502.
14. Wolfs TF, de Jong JJ, Van den Berg H, Tijnagel JM, Krone WJ,
Goudsmit J: Evolution of sequences encoding the principal
neutralization epitope of human immunodeficiency virus 1 is
host dependent, rapid, and continuous.  Proc Natl Acad Sci U S A
1990, 87:9938-9942.
15. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ,
Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT: Adaptive evo-
lution of human immunodeficiency virus-type 1 during the
natural course of infection.  Science 1996, 272:537-542.
16. Zhang L, Diaz RS, Ho DD, Mosley JW, Busch MP, Mayer A: Host-
specific driving force in human immunodeficiency virus type
1 evolution in vivo.  J Virol 1997, 71:2555-2561.
17. Markham RB, Wang WC, Weisstein AE, Wang Z, Munoz A, Temple-
ton A, Margolick J, Vlahov D, Quinn T, Farzadegan H, Yu XF: Pat-
terns of HIV-1 evolution in individuals with differing rates of
CD4 T cell decline.  Proc Natl Acad Sci U S A 1998, 95:12568-12573.
18. Riddle TM, Shire NJ, Sherman MS, Franco KF, Sheppard HW, Nelson
JA: Sequential turnover of human immunodeficiency virus
type 1 env throughout the course of infection.  J Virol 2006,
80:10591-10599.
19. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, Margolick JB,
Buck C, Siliciano JD, Doms RW, Siliciano RF: Characterization of
chemokine receptor utilization of viruses in the latent reser-
voir for human immunodeficiency virus type 1.  J Virol 2000,
74:7824-7833.
20. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Tay-
lor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D: Genetic and
functional analysis of full-length human immunodeficiency
virus type 1 env genes derived from brain and blood of
patients with AIDS.  J Virol 2003, 77:12336-12345.
21. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson
G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, Beddows
S, Weber J, Sharp PM, Shaw GM, Hahn BH: Molecular cloning and
analysis of functional envelope genes from human immuno-
deficiency virus type 1 sequence subtypes A through G. The
WHO and NIAID Networks for HIV Isolation and Charac-
terization.  J Virol 1996, 70:1651-1667.
22. Zhang PF, Chen X, Fu DW, Margolick JB, Quinnan GV Jr.: Primary
virus envelope cross-reactivity of the broadening neutraliz-
ing antibody response during early chronic human immuno-
deficiency virus type 1 infection.  J Virol 1999, 73:5225-5230.
23. Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H,
Robinson J, van der Groen G, Quinnan GV Jr.: Neutralization and
infectivity characteristics of envelope glycoproteins from
human immunodeficiency virus type 1 infected donors
whose sera exhibit broadly cross-reactive neutralizing activ-
ity.  Virology 2006, 347:36-51.
24. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M,
Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Sala-
zar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC:
Human immunodeficiency virus type 1 env clones from
acute and early subtype B infections for standardized assess-
ments of vaccine-elicited neutralizing antibodies.  J Virol 2005,
79:10108-10125.
25. Skrabal K, Saragosti S, Labernardiere JL, Barin F, Clavel F, Mammano
F: Human immunodeficiency virus type 1 variants isolated
from single plasma samples display a wide spectrum of neu-
tralization sensitivity.  J Virol 2005, 79:11848-11857.
26. Trkola A, Kuster H, Leemann C, Ruprecht C, Joos B, Telenti A, Hir-
schel B, Weber R, Bonhoeffer S, Gunthard HF: Human immunode-
ficiency virus type 1 fitness is a determining factor in viral
rebound and set point in chronic infection.  J Virol 2003,
77:13146-13155.
27. Jansson M, Backstrom E, Bjorndal A, Holmberg V, Rossi P, Fenyo EM,
Popovic M, Albert J, Wigzell H: Coreceptor usage and RANTES
sensitivity of non-syncytium-inducing HIV-1 isolates
obtained from patients with AIDS.  J Hum Virol 1999, 2:325-338.
28. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiem-
stra H, Schuitemaker H: Decreasing sensitivity to RANTES
(regulated on activation, normally T cell-expressed and -
secreted) neutralization of CC chemokine receptor 5-using,
non-syncytium-inducing virus variants in the course of
human immunodeficiency virus type 1 infection.  J Infect Dis
2003, 188:864-872.
29. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, Olde
B, Owman C, Jansson M, Fenyo EM: Coevolution of RANTES sen-
sitivity and mode of CCR5 receptor use by human immuno-
deficiency virus type 1 of the R5 phenotype.  J Virol 2004,
78:11807-11815.
30. Torre VS, Marozsan AJ, Albright JL, Collins KR, Hartley O, Offord RE,
Quinones-Mateu ME, Arts EJ: Variable sensitivity of CCR5-tropicRetrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
Page 15 of 16
(page number not for citation purposes)
human immunodeficiency virus type 1 isolates to inhibition
by RANTES analogs.  J Virol 2000, 74:4868-4876.
31. Repits J, Oberg M, Esbjornsson J, Medstrand P, Karlsson A, Albert J,
Fenyo EM, Jansson M: Selection of human immunodeficiency
virus type 1 R5 variants with augmented replicative capacity
and reduced sensitivity to entry inhibitors during severe
immunodeficiency.  J Gen Virol 2005, 86:2859-2869.
32. Stalmeijer EH, Van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA,
Schols D, Schuitemaker H: In vivo evolution of X4 human immu-
nodeficiency virus type 1 variants in the natural course of
infection coincides with decreasing sensitivity to CXCR4
antagonists.  J Virol 2004, 78:2722-2728.
33. Koning FA, Koevoets C, van der Vorst TJ, Schuitemaker H: Sensitiv-
ity of primary R5 HTV-1 to inhibition by RANTES correlates
with sensitivity to small-molecule R5 inhibitors.  Antivir Ther
2005, 10:231-237.
34. Labrosse B, Labernardiere JL, Dam E, Trouplin V, Skrabal K, Clavel F,
Mammano F: Baseline susceptibility of primary human immu-
nodeficiency virus type 1 to entry inhibitors.  J Virol 2003,
77:1610-1613.
35. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M,
Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E,
Doms RW: Sensitivity of HIV-1 to entry inhibitors correlates
with envelope/coreceptor affinity, receptor density, and
fusion kinetics.  Proc Natl Acad Sci U S A 2002, 99:16249-16254.
36. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC,
Doms RW: Impact of mutations in the coreceptor binding site
on human immunodeficiency virus type 1 fusion, infection,
and entry inhibitor sensitivity.  J Virol 2004, 78:5476-5485.
37. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T: An anti-CCR5
monoclonal antibody and small molecule CCR5 antagonists
synergize by inhibiting different stages of human immunode-
ficiency virus type 1 entry.  Virology 2006, 352:477-484.
38. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer
M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Gunthard
HF, Trkola A: Virus isolates during acute and chronic human
immunodeficiency virus type 1 infection show distinct pat-
terns of sensitivity to entry inhibitors.  J Virol 2005,
79:8454-8469.
39. Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Boni J,
Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R,
Gunthard HF: Low human immunodeficiency virus envelope
diversity correlates with low in vitro replication capacity and
predicts spontaneous control of plasma viremia after treat-
ment interruptions.  J Virol 2005, 79:9026-9037.
40. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J: Replicative function
and neutralization sensitivity of envelope glycoproteins from
primary and T-cell line-passaged human immunodeficiency
virus type 1 isolates.  J Virol 1995, 69:4413-4422.
41. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ: Extensive
recombination among human immunodeficiency virus type
1 quasispecies makes an important contribution to viral
diversity in individual patients.  J Virol 2006, 80:2472-2482.
42. Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, Hance AJ:
Contribution of recombination to the evolution of human
immunodeficiency viruses expressing resistance to antiret-
roviral treatment.  J Virol 2007, 81:7620-7628.
43. Murakami T, Freed EO: Genetic evidence for an interaction
between human immunodeficiency virus type 1 matrix and
alpha-helix 2 of the gp41 cytoplasmic tail.  J Virol 2000,
74:3548-3554.
44. West JT, Weldon SK, Wyss S, Lin X, Yu Q, Thali M, Hunter E: Muta-
tion of the dominant endocytosis motif in human immuno-
deficiency virus type 1 gp41 can complement matrix
mutations without increasing Env incorporation.  J Virol 2002,
76:3338-3349.
45. Davis MR, Jiang J, Zhou J, Freed EO, Aiken C: A mutation in the
human immunodeficiency virus type 1 Gag protein destabi-
lizes the interaction of the envelope protein subunits gp120
and gp41.  J Virol 2006, 80:2405-2417.
46. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms
RW, Baribaud F: Truncation of the cytoplasmic domain
induces exposure of conserved regions in the ectodomain of
human immunodeficiency virus type 1 envelope protein.  J
Virol 2002, 76:2683-2691.
47. Gabuzda DH, Lever A, Terwilliger E, Sodroski J: Effects of deletions
in the cytoplasmic domain on biological functions of human
immunodeficiency virus type 1 envelope glycoproteins.  J Virol
1992, 66:3306-3315.
4 8 . L a m b e l e  M ,  L a b r o s s e  B ,  R o c h  E ,  M o r e a u  A ,  V e r r i e r  B ,  B a r i n  F ,
Roingeard P, Mammano F, Brand D: Impact of natural polymor-
phism within the gp41 cytoplasmic tail of human immunode-
ficiency virus type 1 on the intracellular distribution of
envelope glycoproteins and viral assembly.  J Virol 2007,
81:125-140.
49. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX,
McLaughlin S, Shankarappa R, Margolick JB, Mullins JI: Improved
coreceptor usage prediction and genotypic monitoring of
R5-to-X4 transition by motif analysis of human immunodefi-
ciency virus type 1 env V3 loop sequences.  J Virol 2003,
77:13376-13388.
50. Fulcher JA, Hwangbo Y, Zioni R, Nickle D, Lin X, Heath L, Mullins JI,
Corey L, Zhu T: Compartmentalization of human immunode-
ficiency virus type 1 between blood monocytes and CD4+ T
cells during infection.  J Virol 2004, 78:7883-7893.
51. Sullivan ST, Mandava U, Evans-Strickfaden T, Lennox JL, Ellerbrock
TV, Hart CE: Diversity, divergence, and evolution of cell-free
human immunodeficiency virus type 1 in vaginal secretions
and blood of chronically infected women: associations with
immune status.  J Virol 2005, 79:9799-9809.
52. Pillai SK, Good B, Pond SK, Wong JK, Strain MC, Richman DD, Smith
DM: Semen-specific genetic characteristics of human immu-
nodeficiency virus type 1 env.  J Virol 2005, 79:1734-1742.
53. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J,
Simmonds P, Clapham PR: Biological analysis of human immun-
odeficiency virus type 1 R5 envelopes amplified from brain
and lymph node tissues of AIDS patients with neuropathol-
ogy reveals two distinct tropism phenotypes and identifies
envelopes in the brain that confer an enhanced tropism and
fusigenicity for macrophages.  J Virol 2004, 78:6915-6926.
54. Ghaffari G, Tuttle DL, Briggs D, Burkhardt BR, Bhatt D, Andiman
WA, Sleasman JW, Goodenow MM: Complex determinants in
human immunodeficiency virus type 1 envelope gp120 medi-
ate CXCR4-dependent infection of macrophages.  J Virol 2005,
79:13250-13261.
55. Poumbourios P, Maerz AL, Drummer HE: Functional evolution of
the HIV-1 envelope glycoprotein 120 association site of glyc-
oprotein 41.  J Biol Chem 2003, 278:42149-42160.
56. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner
L, Shaw GM, Hunter E: Sensitivity of human immunodeficiency
virus type 1 to fusion inhibitors targeted to the gp41 first
heptad repeat involves distinct regions of gp41 and is consist-
ently modulated by gp120 interactions with the coreceptor.
J Virol 2001, 75:8605-8614.
57. Edwards CT, Holmes EC, Pybus OG, Wilson DJ, Viscidi RP, Abrams
EJ, Phillips RE, Drummond AJ: Evolution of the human immuno-
deficiency virus envelope gene is dominated by purifying
selection.  Genetics 2006, 174:1441-1453.
58. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW:
Clinical resistance to enfuvirtide does not affect susceptibil-
ity of human immunodeficiency virus type 1 to other classes
of entry inhibitors.  J Virol 2007, 81:3240-3250.
59. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ: Natural variation in
the v3 crown of human immunodeficiency virus type 1
affects replicative fitness and entry inhibitor sensitivity.  J Virol
2007, 81:8258-8269.
60. Biscone MJ, Miamidian JL, Muchiri JM, Baik SS, Lee FH, Doms RW,
Reeves JD: Functional impact of HIV coreceptor-binding site
mutations.  Virology 2006, 351:226-236.
61. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA:
Determinants of human immunodeficiency virus type 1
baseline susceptibility to the fusion inhibitors enfuvirtide and
T-649 reside outside the peptide interaction site.  J Virol 2004,
78:7582-7589.
62. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G,
Ruker F, Katinger H: A conserved neutralizing epitope on gp41
of human immunodeficiency virus type 1.  J Virol 1993,
67:6642-6647.
63. Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krauss-
lich HG, Dittmar MT: T20-insensitive HIV-1 from naive patientsPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2008, 5:23 http://www.retrovirology.com/content/5/1/23
Page 16 of 16
(page number not for citation purposes)
exhibits high viral fitness in a novel dual-color competition
assay on primary cells.  Virology 2005, 333:251-262.
64. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Ali-
zon M: Determinants for sensitivity of human immunodefi-
ciency virus coreceptor CXCR4 to the bicyclam AMD3100.  J
Virol 1998, 72:6381-6388.
65. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ,
Clavel F, Mammano F: Impact of antiretroviral treatment on
the tropism of HIV-1 plasma virus populations.  Aids 2003,
17:809-814.
66. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Ali-
zon M, Scarlatti G, Clavel F, Mammano F: Determination of core-
ceptor usage of human immunodeficiency virus type 1 from
patient plasma samples by using a recombinant phenotypic
assay.  J Virol 2001, 75:251-259.
67. Tajima F, Nei M: Estimation of evolutionary distance between
nucleotide sequences.  Mol Biol Evol 1984, 1:269-285.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral